{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:50:52Z","timestamp":1755798652264,"version":"3.44.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,19]]},"DOI":"10.7759\/cureus.90480","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T12:50:53Z","timestamp":1755607853000},"source":"Crossref","is-referenced-by-count":0,"title":["Improvement in Physical Function Associated With Burosumab in a Patient With X-linked Hypophosphatemia: A Case Report"],"prefix":"10.7759","author":[{"given":"Masato","family":"Fukushima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuki","family":"Hashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Matsuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23","volume":"26","author":"White KE","year":"2000","unstructured":"White KE, Evans WE, O'Riordan JL, et al.. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000, 26:345-8. 10.1038\/81664","journal-title":"Nat Genet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0587","article-title":"The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases","volume":"64","author":"Feng J","year":"2017","unstructured":"Feng J, Jiang Y, Wang O, et al.. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J. 2017, 64:675-83. 10.1507\/endocrj.EJ16-0587","journal-title":"Endocr J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna KL","year":"2019","unstructured":"Insogna KL, Rauch F, Kamenick\u00fd P, et al.. Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res. 2019, 34:2183-91. 10.1002\/jbmr.3843","journal-title":"J Bone Miner Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale AA","year":"2019","unstructured":"Portale AA, Carpenter TO, Brandi ML, et al.. Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int. 2019, 105:271-84. 10.1007\/s00223-019-00568-3","journal-title":"Calcif Tissue Int"},{"key":"ref5","article-title":"Serum phosphorus in protein energy malnutrition","volume":"1","author":"Freiman I","year":"1982","unstructured":"Freiman I, Pettifor JM, Moodley GM. Serum phosphorus in protein energy malnutrition. J Pediatr Gastroenterol Nutr. 1982, 1:547-50.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner D","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, et al.. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019, 15:435-55. 10.1038\/s41581-019-0152-5","journal-title":"Nat Rev Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4146","article-title":"The muscle-bone relationship in X-linked hypophosphatemic rickets","volume":"98","author":"Veilleux LN","year":"2013","unstructured":"Veilleux LN, Cheung MS, Glorieux FH, Rauch F. The muscle-bone relationship in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2013, 98:990-5. 10.1210\/jc.2012-4146","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/367297-improvement-in-physical-function-associated-with-burosumab-in-a-patient-with-x-linked-hypophosphatemia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T12:50:53Z","timestamp":1755607853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/367297-improvement-in-physical-function-associated-with-burosumab-in-a-patient-with-x-linked-hypophosphatemia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.90480","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,19]]}}}